CONMED Acquires Biorez, Inc. to Expand Sports Medicine Bioinductive Scaffold Technology

CONMED Acquires In2Bones Global, Inc.

June 13, 2022

Medical Devices

CONMED Corporation (NYSE: CNMD) entered into a definitive agreement to acquire privately-held In2Bones Global, Inc. for $145 million in cash consideration at closing, plus up to $110 million in growth-based earnout payments over four years. The company later announced the acquisition was completed.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Mirion Technologies Acquires Biodex Medical Systems

September 1, 2020

Medical Devices

Mirion Technologies, a San Ramon-based, PE-backed provider of radiation detection and measurement solutions, acquired Biodex Medical Systems, Inc. effective September 1, 2020. Biodex, a manufacturer of nuclear medicine instruments, medical imaging equipment and rehabilitation systems headquartered in Shirley, New York, will expand Mirion's medical device and imaging capabilities as part of Mirion's strategic plan to grow its medical business.

Agilent Technologies to Acquire Biocare Medical for $950 Million

March 9, 2026

Healthcare Services

Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, in an all-cash transaction valued at $950 million. The deal is designed to expand Agilent’s pathology portfolio—especially immunohistochemistry—and is expected to close no later than Agilent’s fourth fiscal quarter of 2026.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.